Metabolic Effects of Fluoxetine in Adults with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Placebo-Controlled Trials

Zi Ye, Lili Chen, Zhen Yang, Qin Li, Ying Huang, Min He, Shuo Zhang, Zhaoyun Zhang, Xuanchun Wang, Weiwei Zhao, Ji Hu, Chao Liu, Shen Qu and Renming Hu

PLOS ONE, 2011, vol. 6, issue 7, 1-7

Abstract: Background: The prevalence of obesity and diabetes is increasing dramatically throughout the world. Studies have shown that excess adiposity is a critical predictor of new onset T2DM. This meta-analysis is aimed to assess the metabolic effects of fluoxetine in T2DM. Methods and Findings: Electronic search was conducted in the database Medline, PubMed, EMBASE, and the Cochrane library, from inception through to March 2011. A systematic review of the studies on the metabolic effects of fluoxetine in T2DM was performed. The weighted mean difference (WMD) and its 95% CI were calculated from the raw data extracted from the original literature. The software Review Manager (version 4.3.1) and Stata (version 11.0) were applied for meta-analysis. Five randomized, placebo-controlled trials were included in the meta-analysis. According to WMD calculation, fluoxetine therapy led to 4.27 Kg of weight loss (95%CI 2.58–5.97, P

Date: 2011
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021551 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 21551&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0021551

DOI: 10.1371/journal.pone.0021551

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().